Carlos Enrique Vigil

Carlos Enrique Vigil

Auto-generated profile, based on publicly available information

Carlos Enrique Vigil

Bristol Myers Squibb, Summit, NJ

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KNKiran Naqvi
Kiran Naqvi
GGGuillermo Garcia-Manero
Guillermo Garcia-Manero
SSSagar Sardesai
Sagar Sardesai
JOJeong Oh
Jeong Oh
CVCarlos E. Vigil
Carlos E. Vigil
MSMaria E. Suarez-Almazor
Maria E. Suarez-Almazor
Purpose: Patients with cancer often experience comorbidities that may affect their prognosis and outcome. The objective of this study was to determine the effect of comorbidities on the survival of patients with myelodysplastic syndrome (MDS).Patients and Methods: We conducted a retrospective cohort study of 600 consecutive patients with MDS who presented to MD Anderson Cancer Center from January 2002 to December 2004. The Adult Comorbidity Evaluation-27 (ACE-27) scale was used to assess comorbidities. Data on demographics, International Prognostic Scoring System (IPSS), treatment, and outcome (leukemic transformation and survival) were collected. Kaplan-Meier methods and Cox regression were used to assess survival. A prognostic model incorporating baseline comorbidities with age and IPSS was developed to predict survival.Results: Overall median survival was 18.6 months. According to the ACE-27 categories, median survival was 31.8, 16.8, 15.2, and 9.7 months for those with none, mild, moderate, and severe comorbidities, respectively (P < .001). Adjusted hazard ratios were 1.3, 1.6, and 2.3 for mild, moderate, and severe comorbidities, respectively, compared with no comorbidities (P < .001). A final pognostic model including age, IPSS, and comorbidity score predicted median survival of 43.0, 23.0, and 9.0 months for lower-, intermediate-, and high-risk groups, respectively (P < .001).Conclusion: Comorbidities have a significant impact on the survival of patients with MDS. Patients with severe comorbidity had a 50% decrease in survival, independent of age and IPSS risk group. A comprehensive assessment of the severity of comorbidities helps predict survival in patients with MDS.

1 August 2010 in Clinical Breast Cancer
Verified
Journal Article
Closed access
CVCarlos S. Vallejos
Carlos S. Vallejos
HGHenry Leonidas Gomez
Henry Leonidas Gomez
WCWilder R. Cruz
Wilder R. Cruz
JPJoseph Pinto
Joseph Pinto
RDRichard R. Dyer
Richard R. Dyer
CVCarlos E. Vigil
Carlos E. Vigil

10 December 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SMS. Tariq Mahmood
S. Tariq Mahmood
SASamuel Agresta
Samuel Agresta
CVCarlos E. Vigil
Carlos E. Vigil
XZXiuhua Zhao
Xiuhua Zhao
GHGang Han
Gang Han
ACAlberto Chiappori
Alberto Chiappori
Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable molecular alterations, often treated as a single disease. Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor active in other solid tumors carrying similar alterations (i.e., imatinib mesylate‐refractory gastrointestinal stromal tumors). This single‐institution phase II study investigated the safety and efficacy of sunitinib malate in three common STS subtypes. Patients with documented unresectable or metastatic STS (liposarcoma, leiomyosarcoma and malignant fibrous histiocytoma [MFH]), measurable disease, and 3 or less prior lines of therapy were eligible. Treatment consisted of sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks. Forty‐eight patients were enrolled, and 35% were heavily pretreated (≥2 prior lines of chemotherapy). The safety profile resembled previously known sunitinib malate toxicities. Median progression‐free and overall survivals for liposarcoma, leiomyosarcoma, and MFH were 3.9 and 18.6, 4.2 and 10.1 and 2.5 and 13.6 months, respectively. The 3‐month progression‐free rates in the untreated and pretreated (chemotherapy) patients with liposarcoma, leiomyosarcoma and MFH were 75% and 69.2%, 60%, and 62.5% and 25% and 44.4%, respectively. With the caveats that a minority of patients with potentially indolent or low‐grade disease could have been included and the small numbers, a 3‐month progression‐free rate of >40% suggests activity for sunitinib malate at least in liposarcomas and leiomyosarcomas. Thus, we believe that further investigation in these susceptible STS subtypes is warranted.

1 August 2013 in Leukemia Research
Verified
Journal Article
Closed access
OUOmar Al Ustwani
Omar Al Ustwani
LFLaurie A. Ford
Laurie A. Ford
SSSheila J.N. Sait
Sheila J.N. Sait
ABAnne Marie W. Block
Anne Marie W. Block
MBMaurice Barcos
Maurice Barcos
MWMeir Wetzler
Meir Wetzler

20 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
Eunice S WangEunice S Wang
Eunice S Wang
AGAaron D. Goldberg
Aaron D. Goldberg
MTMartin Tallman
Martin Tallman
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter
CKChatchada Karanes
Chatchada Karanes
RSRichard M. Stone
Richard M. Stone
PURPOSE: Crenolanib is a second-generation tyrosine kinase inhibitor with activity against FLT3-ITD– and TKD-mutant AML. We conducted a trial of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML. METHODS: Eligible patients were 18 years and older. Induction chemotherapy consisted of cytarabine (100 mg/m2) continuous infusion on days 1-7 and anthracycline (daunorubicin 60-90 mg/m2 or idarubicin 12 mg/m2, once daily) on days 1-3 followed by consolidation with high-dose cytarabine (1-3 g/m2 twice daily on days 1, 3, 5) and/or allogeneic transplant. Crenolanib (100 mg thrice a day) was given from day 9 until 72 hours before the next cycle, after consolidation, and for 12 months after consolidation or transplant. RESULTS: Forty-four patients (median age, 57; range, 19-75 years) were enrolled. Thirty-six had FLT3-ITD, and 11 had FLT3-TKD mutations. European LeukemiaNet 2017 disease risk was favorable in 34%, intermediate in 30%, and adverse in 36%. The overall response rate was 86% (complete remission [CR], 77%; CR with incomplete count recovery [CRi], 9%): 90% in patients 60 years and younger and 80% in older patients. Measurable residual disease–negative CR/CRi rates were 89% and 45%, respectively. With a 45-month follow-up, median overall survival has not been reached and the median event-free survival was 44.7 months. Among younger patients, the estimated 3-year survival was 71.4% with 15% cumulative incidence of relapse. Treatment-related serious adverse events included febrile neutropenia, diarrhea, and nausea. The median time to platelets ≥100,000/µL and absolute neutrophil count ≥1,000/µL during induction was 29 and 32 days, respectively. No new FLT3-mutant clones were detected at relapse in patients completing consolidation. CONCLUSION: Crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML results in high rate of deep responses and long-term survival with acceptable toxicity. A randomized trial of crenolanib versus midostaurin plus chemotherapy in younger patients is ongoing.

1 January 2010 in Cancer Control
Verified
Journal Article
Open access
PDF file
JOJose Ortega
Jose Ortega
CVCarlos E. Vigil
Carlos E. Vigil
CCCatherine Chodkiewicz
Catherine Chodkiewicz
Several molecular targeting agents are available and being used in patients with colorectal cancer, and many others are being tested clinically. The authors review and present the biology and use, including predictive testing, of the agents currently approved for use in colorectal cancer as well as current data on several newer tyrosine kinase inhibitors that are undergoing clinical trials. The angiogenesis inhibitor bevacizumab and the two EGFR inhibitors cetuximab and panitumumab are currently the three targeted agents approved in colorectal cancer. Recent studies show that the combined use of bevacizumab and EGFR inhibitors may lead to increased toxicity and inferior outcome. Much remains to be understood regarding these drugs and other targeted therapies as well as the underlying mechanism of tumor resistance or responsiveness to treatment. Their optimal use and sequencing with other treatment modalities such as surgery need to be further refined. There is a crucial need for identification of predictive markers of response and identification of possible negative interactions between targeted agents so that we can better select patients likely to respond to treatment.